Research

Omicron evades some but not all monoclonal antibodies: study

A new study found that several, but not all, of the human monoclonal antibodies used clinically to prevent patients from becoming severely ill from COVID-19 may not be protective against the Omicron variant now sweeping across the United States.

From left, J.Court Reese, Stephanie Moore-Lotridge, PhD, Breanne Gibson, PhD, and Jonathan Schoenecker, MD, PhD, are discovering ways to prevent adverse outcomes in orthopaedic surgery.

Study identifies molecular trigger of severe injury-induced inflammatory response

Vanderbilt researchers have discovered that early inappropriate activation of the enzyme plasmin caused by severe injury is a trigger of systemic inflammatory response syndrome and resulting organ failure.

Clinical score can guide PRRT therapy decisions for neuroendocrine tumors

A clinical score system developed by researchers at Vanderbilt-Ingram Cancer Center (VICC) has been validated that can guide peptide receptor radionuclide therapy treatment decisions.

Ensuring the “best possible” medication history

About 80% of hospital admission electronic records were missing a drug prescribed to an older adult, Vanderbilt researchers found, highlighting the need for a multipronged approach to address medication discrepancies and support safe prescribing practices.

H. pylori, lipid loss and stomach cancer

H. pylori infection — a strong risk factor for stomach cancer — changes the composition of stomach lipids, which could offer new biomarkers for detecting premalignant changes, Vanderbilt researchers discovered.

Vanderbilt biostatisticians launch Cancer-Immu data portal for predicting response to immune checkpoint blockade immunotherapy

A new data portal called Cancer-Immu established by a team of Vanderbilt University Medical Center biostatisticians can help cancer clinicians and researchers predict which patients will respond to immune checkpoint inhibitors.

1 41 42 43 44 45 125